Quality of ADR reporting evaluated for remdesivir trials of COVID-19

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2020年 / 1827卷 / 1期
关键词：
D O I：
10.1007/s40278-020-84767-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：10 / 10
相关论文
共 50 条
  • [41] Remdesivir in hospitalized COVID-19 Patients
    Thiem, Helena
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (03): : 111 - +
  • [42] COVID-19: Remdesivir beats Placebo
    不详
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (23)
  • [43] REMDESIVIR AND CARDIAC ARRHYTHMIA IN COVID-19
    Dhaliwal, Lovekirat
    Boparai, Sukhmani
    Davila-Chapa, Cesar
    Krishnan, Prathik
    Dominic, Paari
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 37 - 37
  • [44] Correction to: Remdesivir: A Review in COVID-19
    Hannah A. Blair
    Drugs, 2023, 83 (14) : 1349 - 1349
  • [45] To Determine the Efficacy of Remdesivir in Covid-19
    Hameed, A.
    Mehmood, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S42 - S42
  • [46] Remdesivir for patients with severe COVID-19
    Augustin, M.
    Hallek, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (06): : 644 - 645
  • [47] Covid-19: What now for remdesivir?
    Hsu, Jeremy
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
  • [48] Inhaled remdesivir treatment for COVID-19
    Yang, C.
    Zhag, H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2021, 25 (10) : 788 - 790
  • [49] Evaluation of reporting quality of randomized controlled trials in patients with COVID-19 using the CONSORT statement
    Yin, Yuhuan
    Shi, Fugui
    Zhang, Yiyin
    Zhang, Xiaoli
    Ye, Jianying
    Zhang, Juxia
    PLOS ONE, 2021, 16 (09):
  • [50] Transparency and reporting characteristics of COVID-19 randomized controlled trials
    Kapp, Philipp
    Esmail, Laura
    Ghosn, Lina
    Ravaud, Philippe
    Boutron, Isabelle
    BMC MEDICINE, 2022, 20 (01)
12345